Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B

Chan, Henry Lik YuenLim, Young-SukSeto, Wai Kay WalterAgarwal, KoshBrunetto, Maurizia R.Janssen, Harry L. A.Caruntu, Florin2024-04-242024-04-2420180270-91391527-3350https://hdl.handle.net/11468/23162Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting -- NOV 09-13, 2018 -- San Francisco, CA[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis BThree Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis BConference Object68227A228AWOS:000446020500384Q1